On May 10, 2023, after the market closed, Canopy Growth announced that its audited consolidated financial statements for the fiscal year ended March 31, 2022 and the quarters ended June 30, 2022, September 30, 2022 and December 31, 2022 should no longer be relied upon, and would need to be restated. The Company also disclosed that it “identified certain trends in the booking of sales by the [BioSteel] business unit for further review.” The Company specified that “although the BioSteel Review remains ongoing, the Company has preliminarily identified material misstatements” and that “the correction of the misstatements is expected to reduce certain revenues previously recognized.” On this news, Canopy Growth’s stock price fell $0.18, or 14.8%, to close at $1.04 per share on May 11, 2023, on unusually heavy trading volume.

According to the complaint, Canopy and its senior executives failed to disclose to investors that: (1) material weaknesses existed in the Company’s internal controls over accounting and financial reporting; (2) as a result, the Company improperly booked sales of its BioSteel business unit; (3) as a result, the Company’s revenue was overstated.

Investors who purchased or acquired Canopy securities between May 31, 2022 and May 10, 2023, may no later than July 24, 2023, seek to be appointed as a lead plaintiff representative of the class.